Phase II evaluation of suramin in advanced renal cell carcinoma - A Southwest Oncology Group study

Authors
Schroder, LE Lew, D Flanigan, RC Eisenberger, MA Seay, TE Hammond, N Needles, BM Crawford, ED
Citation
Le. Schroder et al., Phase II evaluation of suramin in advanced renal cell carcinoma - A Southwest Oncology Group study, UROL ONCOL, 6(4), 2001, pp. 145-148
Citations number
12
Categorie Soggetti
Urology & Nephrology
Journal title
UROLOGIC ONCOLOGY
ISSN journal
10781439 → ACNP
Volume
6
Issue
4
Year of publication
2001
Pages
145 - 148
Database
ISI
SICI code
1078-1439(200107/08)6:4<145:PIEOSI>2.0.ZU;2-Z
Abstract
Twenty-two eligible patients with advanced renal carcinoma were treated wit h suramin utilizing a fixed dose regimen. Therapy was reasonably well toler ated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 p atients (50%) having a maximum toxicity of grade 3. There were no responder s; median survival was 10 months. Suramin is not an active agent in advance d renal carcinoma. (C) 2001 Elsevier Science Inc. All rights reserved.